Fundz

Kaida Bio Pharma reported raising $1.57 Million in an initial SEC Form D filing, from an offering of $3 Million

PRIVATEJan 21, 2026Late filing, first sale Oct 24, 2023

Amount Raised

$1.57 Million

$1.57 Million sold, per SEC Form D (first sale Oct 24, 2023)

Round Type

Seed

Fort LauderdaleBiotechnology

Who to call at Kaida BioPharma, and when

A new round usually means Kaida BioPharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kaida BioPharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kaida BioPharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kaida BioPharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kaida BioPharma

Location

416 SW 1st Avenue

Fort Lauderdale, Florida, United States

About

Kaida BioPharma was founded on the research principles and clinical evidence of G129R, a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kaida BioPharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsRobbin, Director of Operations hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Kaida BioPharma's next move

See what Strategic adds

Kaida BioPharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.